The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

According to The Business Research Company’s Age-Related Macular Degeneration Global Market Report 2024, the age-related macular degeneration market is expected to show promising growth in the forecast period.

The age-related macular degeneration (AMD) market has witnessed robust growth in recent years, with the market size expanding from $9.17 billion in 2023 to $9.9 billion in 2024, demonstrating a notable compound annual growth rate (CAGR) of 7.9%. This growth is fueled by various factors, including demographic shifts, lifestyle changes, and advancements in diagnostic techniques.

Anticipating Continued Expansion
Looking ahead, the age-related macular degeneration market is poised for significant growth, projected to reach $13.1 billion by 2028, boasting a CAGR of 7.3%. This anticipated growth can be attributed to ongoing research in genetics and biomarkers, emerging therapeutic modalities, and the adoption of telemedicine and remote monitoring, reflecting a promising outlook for the industry.

The Surging Prevalence of Age-Related Macular Degeneration Sparks Growth

• The rising prevalence of age-related macular degeneration (AMD) is expected to drive market growth.
• AMD is a progressive eye condition affecting the macula, impacting central vision.
• Reports indicate a significant increase in global AMD cases, underscoring the urgency for effective treatments.

View More On The Age-Related Macular Degeneration Market Report 2024 – https://www.thebusinessresearchcompany.com/report/age-related-macular-degeneration-global-market-report

Innovations Reshaping AMD Treatment

• Product innovations play a pivotal role in advancing AMD treatment options.
• Genentech’s Susvimo represents a breakthrough in AMD therapy, offering a sustained-release implant for patients with wet AMD.
• Astellas Pharma’s strategic acquisition of IVERIC Bio Inc. signifies the industry’s commitment to expanding treatment options and research capabilities.

Market Segmentation and Strategic Acquisitions

• By Type: Segmented into Wet AMD and Dry AMD, reflecting different disease manifestations.
• By Drug: Includes Eylea, Lucentis, Avastin, and other products, catering to diverse patient needs.
• By Route of Administration: Encompasses Intravenous and Intravitreal administration routes, ensuring treatment accessibility.
• By Distribution Channel: Hospital Pharmacy, Specialty Pharmacy, and Online Pharmacy, offering varied avenues for medication acquisition.

Regional Dynamics:

• North America: Emerged as the largest region in the global AMD market in 2023, highlighting significant market presence and growth opportunities.
• Asia-Pacific: Expected to be the fastest-growing region, driven by increased healthcare investments and rising AMD prevalence.

In conclusion, the age-related macular degeneration market is experiencing remarkable growth propelled by demographic shifts, technological advancements, and strategic acquisitions. As stakeholders continue to prioritize research and innovation, the landscape of AMD treatment is set to evolve, offering new hope and improved quality of life for patients worldwide.

Request A Sample Of The Global Age-Related Macular Degeneration Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=10845&type=smp